March 2023 in “International Journal of Trichology” A man developed temporary hair loss after taking a cancer drug, which might indicate a better treatment response.
January 2023 in “International Journal of Zoological Investigations” Certain genetic variations in IL-16 may increase the risk of alopecia areata.
Tofacitinib significantly improved hair loss and lesions in a patient with overlapping autoimmune disorders.
June 2025 in “bioRxiv (Cold Spring Harbor Laboratory)” In alopecia areata, certain immune cells increase and express a protein linked to immune activation.
March 2026 in “European journal of ecology, biology and agriculture.” Patients with alopecia areata have higher levels of certain immune markers, suggesting new treatment targets.
July 2025 in “International Journal of Molecular Sciences” Blocking CXCL12 can reverse hair loss and fibrosis in androgenetic alopecia.
5 citations
,
February 2024 in “Journal of Investigative Dermatology” Alopecia areata patients have fewer protective regulatory B cells, which may contribute to the disease.
19 citations
,
January 2019 in “JAAD case reports” A medication for skin rash also unexpectedly treated hair loss in a patient.
April 2019 in “Journal of Investigative Dermatology” Blocking LFA-1 prevents hair loss in mice.
20 citations
,
May 2016 in “Journal of Cutaneous Pathology” Using CD123 to detect certain immune cells helps diagnose a type of hair loss condition.
September 2023 in “Journal of the American Academy of Dermatology” CTP-543 is generally safe for treating alopecia areata.
January 2011 in “Annals of dermatology/Annals of Dermatology” A woman's psoriasis improved after hepatitis C treatment with interferon, despite interferon's risk of worsening skin conditions.
Upadacitinib effectively treated a patient with multiple inflammatory conditions.
April 2026 in “Frontiers in Medicine” Upadacitinib effectively treats psoriasis and lichen planus together.
29 citations
,
July 2019 in “Dermatologic Therapy” Dupilumab can both heal and cause hair loss.
October 2022 in “Amplla Editora eBooks” Tocilizumab might be an effective treatment for COVID-19.
Tofacitinib significantly improved symptoms in a patient with overlapping autoimmune disorders.
November 2022 in “Journal of the Endocrine Society” Immunotherapy for cancer caused a patient to develop a condition affecting hormone production, requiring ongoing hormone replacement therapy.
85 citations
,
January 1996 in “International Journal of Cancer” AS101 reduces hair loss from chemotherapy.
April 2023 in “Journal of Investigative Dermatology” Targeting mTOR in myeloid cells may help reduce psoriasis symptoms.
14 citations
,
March 2002 in “The journal of investigative dermatology/Journal of investigative dermatology” Patients with severe alopecia areata have higher levels of MIF, which decrease after successful treatment.
37 citations
,
October 2017 in “Clinical and Experimental Dermatology” Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.
1 citations
,
July 2012 in “Nasza Dermatologia Online” IL-1α levels are higher in alopecia areata patients, suggesting a role in the disease.
April 2026 in “Health care of Tajikistan” Combined therapy reduces inflammation and restores immune balance in alopecia areata patients.
Ivarmacitinib effectively regrows hair in severe alopecia areata.
October 2025 in “International Journal of Dermatology” JAK inhibitors may help treat certain types of hair loss, but more research is needed.
Hit15 shows promise as a COVID-19 treatment by reducing virus infection and inflammation.
April 2026 in “Journal of Inflammation Research” Alopecia areata and atopic dermatitis share immune system issues, and treatments like JAK inhibitors can help both.
3 citations
,
July 2025 in “Clinical and Experimental Dermatology” Ritlecitinib may be more effective for severe alopecia areata than conventional treatments.
15 citations
,
November 2024 in “Journal of Advanced Research” miR-3606-3p reduces skin fibrosis by blocking key signaling pathways.